Tumor markers in clinical oncology

Radiology and Oncology

Volumn 38, Issue 2, 2004, Pages

  Novaković, Srdjan ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Biological; Neoplasms diagnosis; Tumor markers

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; BETA 2 MICROGLOBULIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CATECHOLAMINE; CHORIONIC GONADOTROPIN BETA SUBUNIT; ENZYME; GAMMA GLUTAMYLTRANSFERASE; GROWTH FACTOR RECEPTOR; HORMONE; INSULIN; LACTATE DEHYDROGENASE; LIPOTROPIN; MONOCLONAL ANTIBODY; NEURON SPECIFIC ENOLASE; ONCOFETAL ANTIGEN; PARATHYROID HORMONE; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN S 100; RADIOISOTOPE; THYMIDINE KINASE; THYROGLOBULIN; TUMOR ANTIGEN; TUMOR MARKER;

ASTROCYTOMA; BREAST CANCER; CYTOTOXICITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; ENDOCRINE TUMOR; GLIOBLASTOMA; GYNECOLOGIC CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSCINTIGRAPHY; LEUKEMIA; LUNG CANCER; LYMPHOSCINTIGRAPHY; MELANOMA; MENINGIOMA; NEUROENDOCRINE TUMOR; ONCOLOGY; OVARY CANCER; PANCREAS CANCER; PROGNOSIS; PROSTATE CANCER; REVIEW; SERUM; THYROID CARCINOMA; TREATMENT OUTCOME; TUMOR DIAGNOSIS;

EID: 3142764551     PISSN: 13182099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Hill RP, Tannock IF. Introduction: cancer as a cellular disease. In: Tannock IF, Hill RP, eds. The basic science of oncology. New York: Mc Graw-Hill, 1992: 1-4.
2. Rubin P, ed. Clinical oncology: A multidisciplinary approach for physicians and students, 7th ed. Philadelphia: W.B. Saunders, 1993: 791.
3. Novaković S. Pregled pomembnejših tumorskih označevalcev v klinični onkologiji. Ljubljana: Onkološki inštitut, 2000: 64.
4. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996, by the American Society of Clinical Oncology. J Clin Oncol 1996; 14: 2843-77.
5. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-78.
6. Perkins LG, Slater DE, Sanders KG, Prichard GJ, Serum tumor markers. Am Fam Physician 2003; 68: 1075-82.
7. Malkin A. Tumor markers. In: Tannock IF, Hill RP, eds. The basic science of oncology. New York: Mc Graw-Hill, 1992: 196-206.
8. International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
9. Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ. Predicting outcome to chemotherapy in patients with germ cell tumors: The value of the rate of decline of human chorionic gonadotropin and alpha-fetoprotein during therapy. J Clin Oncol 2001; 19: 2534-41.
10. Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 1990; 8: 1777-81.
11. Novaković S, Serša G. Tumor markers in clinical oncology. In: Benulič T, Serša G, Kovač V, eds. Advances in Radiology and Oncology. Ljubljana: Radiologia Iugoslavica, 1992: 214-20.
12. Ballesta AM, Molina R, Filella X, Jo J, Gimenez N. Carcinoembryonic antigen in stanging and follow-up of patients with solid tumors. Tumour Biol 1995; 16: 32-41.
13. Jezeršek B, Červek J, Rudolf Z, Novakovič S. Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients. Cancer Lett 1996; 110: 137-44.
14. Fletcher RH. Carcionembryonic antigen. Ann Inter Med 1996; 104: 66-74.
15. Abelev GI. Study of the antigenic structure of tumors. Acta Int Cancer 1963; 19: 80-5.
16. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 145-59.
17. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hongkong experience. Hepatology 2000; 31: 330-5.
18. Fowler JE, Platoff GE, Kubrock CA, Stutzman RE. Commercial radioimmuno assay for beta subunit of human chorionic gonadotropin: Falsely positive determinations due to elevated serum luteinizing hormone. Cancer 1982; 49: 136-9.
19. th ed. Philadelphia: Lippincott, Williams & Wilkins, 2001: 1491-518.
20. Cooper HC, Robinson MRG, Whelan P, Ferro AM. Tumor markers in prostate cancer. Cancer 1992; 70: 225-9.
21. Schmechel D, Marangos PJ, Zis AP, Brightman M, Goodwin FK. Brain enolase as specific markers of neuronal and glial cells. Science 1978; 199: 313-5.
22. Carney DN, Ihde DC, Cohen MH, Marangos PJ. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet 1982; 1: 583-5.
23. Wick MR, Brend MD, Scheithauer W, Kovacs K. Neuron specific enolase in neuroendocrine tumors of the thymus, bronchia and skin. Am J Pathol 1983; 79: 703-7.
24. Geraghty JG, Coveney CE, Sherry F, O'Higgins JN, Duffy JM. CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer 1992; 70: 2831-4.
25. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995; 21: 215-45.
26. Novaković S, Serša G, Krošl G, Plesničar S. CEA, MCA and CA 125 tumor markers in pregnant women. Radiol Iugosl 1990; 24: 79-84.
27. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: A pilot randomized controlled trial. Lancet 1999; 353: 1207-10.
28. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85: 350-5.
29. Woodrum LD, Brawer KM, Partin WA, Catalona JW, Southwick CP. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998; 159: 5-12.
30. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998; 279: 1542-7.
31. Ghanem G, Loir B, Morandini R, Sales F, Lienard D, Eggermont A, Lejeune F. On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int J Cancer 2001; 94: 586-90.
32. Jury SC, McAllister JE, MacKie MR. Rising levels of serum S100 protein procedure other evidence of disease progression in patients with malignant melanoma. Br J Derm 2000; 143: 269-74.